Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Austria
  4. Wiener Boerse
  5. Marinomed Biotech AG
  6. Summary
    MARI   ATMARINOMED6

MARINOMED BIOTECH AG

(MARI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Wiener Boerse
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
117.5(c) 118(c) 117.5(c) 118(c) 117(c) Last
763 346 397 777 865 Volume
+1.29% +0.43% -0.42% +0.43% -0.85% Change
More quotes
Estimated financial data (e)
Sales 2021 13,9 M 16,2 M 16,2 M
Net income 2021 -5,44 M -6,37 M -6,37 M
Net Debt 2021 14,3 M 16,7 M 16,7 M
P/E ratio 2021 -31,8x
Yield 2021 -
Sales 2022 56,1 M 65,8 M 65,8 M
Net income 2022 23,3 M 27,4 M 27,4 M
Net cash position 2022 13,7 M 16,1 M 16,1 M
P/E ratio 2022 7,38x
Yield 2022 -
Capitalization 173 M 202 M 202 M
EV / Sales 2021 13,5x
EV / Sales 2022 2,83x
Nbr of Employees 42
Free-Float 61,2%
More Financials
Company
Marinomed Biotechnologie GmbH is an Austria-based biopharmaceutical company engaged in the pharmaceuticals industry. The Company develops anti-viral and immunological therapies, such as nasal sprays, using the antiviral respiratory technology platform MAVIREX, which target more than 200 different respiratory virus strains based on Carragelose, a red algae derived polymer. The company also offers products for the... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Marinomed Biotech AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MARINOMED BIOTECH AG
09/23MARINOMED BIOTECH : Investor Relations to be Strengthened by Stephanie Kniep
PU
09/23PRESS RELEASE : Marinomed's Investor Relations to be Strengthened by Stephanie Kniep
DJ
09/09MARINOMED BIOTECH : publishes clinical data on efficacy of Carragelose lozenges against re..
PU
09/09PRESS RELEASE : Marinomed Biotech AG publishes clinical data on efficacy of Carragelose lo..
DJ
09/09PRESS RELEASE : Marinomed Biotech AG publishes -2-
DJ
08/25MARINOMED BIOTECH : Investor Presentation H1 2021
PU
08/25Marinomed Biotech AG Reports Earnings Results for the Second Quarter Ended June 30, 202..
CI
08/25MARINOMED BIOTECH : Reports Financial Results for 1st Half 2021 with significant revenue g..
PU
08/25PRESS RELEASE : Marinomed Biotech AG Reports Financial Results for 1st Half 2021 with sign..
DJ
08/25PRESS RELEASE : Marinomed Biotech AG Reports -2-
DJ
08/25Marinomed Biotech AG Provides Earnings Guidance for the Fiscal Year 2021
CI
08/25MARINOMED BIOTECH : Half-Year Financial Report 2021
PU
08/13MARINOMED BIOTECH : Conference Call Invitation - Half-Year Results 2021
PU
07/15MARINOMED BIOTECH : announces grant of Chinese Patent covering the proprietary Marinosolv ..
PU
07/15PRESS RELEASE : Marinomed Biotech AG announces grant of Chinese Patent covering the propri..
DJ
More news
News in other languages on MARINOMED BIOTECH AG
09/23Marinomed Biotech AG verstärkt Investor Relations mit Stephanie Kniep
09/21GBC AG : 11. ZKK - Zürcher Kapitalmarkt Konferenz - voller Erfolg - Unternehmenspräsentati..
09/09Marinomed Biotech AG veröffentlicht -2-
08/25PTA-AFR : Marinomed Biotech AG: Halbjahresfinanzbericht gemäß ž 125 BörseG
08/25DGAP-NEWS : Marinomed Biotech AG meldet -2-
More news
Chart MARINOMED BIOTECH AG
Duration : Period :
Marinomed Biotech AG Technical Analysis Chart | MARI | ATMARINOMED6 | MarketScreener
Technical analysis trends MARINOMED BIOTECH AG
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 117,00 €
Average target price 163,67 €
Spread / Average Target 39,9%
EPS Revisions
Managers and Directors
Andreas Grassauer Chairman-Management Board & CEO
Pascal Schmidt Chief Financial Officer
Simon Jules Nebel Chairman-Supervisory Board
Eva Prieschl-Grassauer Chief Scientific Officer
Helmut Baranyovszki Head-Operations
Sector and Competitors
1st jan.Capi. (M$)
MARINOMED BIOTECH AG-1.68%202
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037